HK1253098A1 - 用於治疗癌症的mdm2抑制剂的给药方案 - Google Patents

用於治疗癌症的mdm2抑制剂的给药方案 Download PDF

Info

Publication number
HK1253098A1
HK1253098A1 HK18112485.7A HK18112485A HK1253098A1 HK 1253098 A1 HK1253098 A1 HK 1253098A1 HK 18112485 A HK18112485 A HK 18112485A HK 1253098 A1 HK1253098 A1 HK 1253098A1
Authority
HK
Hong Kong
Prior art keywords
mdm2 inhibitor
dosage regimen
treating
treating cancers
subject
Prior art date
Application number
HK18112485.7A
Other languages
English (en)
Chinese (zh)
Inventor
Ngai-chiu Archie TSE
Shengli CAI
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of HK1253098A1 publication Critical patent/HK1253098A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18112485.7A 2015-10-23 2016-10-21 用於治疗癌症的mdm2抑制剂的给药方案 HK1253098A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245,632 2015-10-23

Publications (1)

Publication Number Publication Date
HK1253098A1 true HK1253098A1 (zh) 2019-06-06

Family

ID=57349101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112485.7A HK1253098A1 (zh) 2015-10-23 2016-10-21 用於治疗癌症的mdm2抑制剂的给药方案

Country Status (8)

Country Link
US (3) US20180296547A1 (cg-RX-API-DMAC7.html)
EP (1) EP3364972A1 (cg-RX-API-DMAC7.html)
JP (4) JP6855472B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180064540A (cg-RX-API-DMAC7.html)
CN (2) CN108135892A (cg-RX-API-DMAC7.html)
HK (1) HK1253098A1 (cg-RX-API-DMAC7.html)
TW (3) TW202332444A (cg-RX-API-DMAC7.html)
WO (1) WO2017069289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
KR20170134462A (ko) * 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2023016977A1 (en) * 2021-08-09 2023-02-16 Boehringer Ingelheim International Gmbh Oral composition comprising a mdm2-antagonist for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007228784B2 (en) * 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
US20100068174A1 (en) * 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
US8288377B2 (en) * 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
US9937178B2 (en) * 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
TWI635089B (zh) * 2013-09-04 2018-09-11 第一三共股份有限公司 螺氧基吲哚衍生物之製造方法
US20160333419A1 (en) * 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers

Also Published As

Publication number Publication date
JP7192011B2 (ja) 2022-12-19
JP2021098750A (ja) 2021-07-01
US20220071975A1 (en) 2022-03-10
US11058673B2 (en) 2021-07-13
JP2023025214A (ja) 2023-02-21
TW202515561A (zh) 2025-04-16
WO2017069289A1 (en) 2017-04-27
JP6855472B2 (ja) 2021-04-07
JP2024164122A (ja) 2024-11-26
CN108135892A (zh) 2018-06-08
JP2018531273A (ja) 2018-10-25
EP3364972A1 (en) 2018-08-29
TW201722427A (zh) 2017-07-01
US20180296547A1 (en) 2018-10-18
TWI806822B (zh) 2023-07-01
KR20180064540A (ko) 2018-06-14
TW202332444A (zh) 2023-08-16
US20190201386A1 (en) 2019-07-04
CN113521069A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MY187540A (en) Compounds active towards bromodomains
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
IN2013MU03583A (cg-RX-API-DMAC7.html)
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
BR112017024163A2 (pt) compostos bicíclicos
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IN2014MU00303A (cg-RX-API-DMAC7.html)
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
IL274008A (en) Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
EP3181136A4 (en) Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
IL271013B (en) Allosteric egfr inhibitors with a modified isoindole, pharmaceutical preparations containing them and their use in medical treatment and/or preventive treatment of cancer
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.